Corteva, Inc. is a global agricultural company providing innovative solutions for crop production, operating in the Basic Materials sector within the Agricultural Inputs industry. The company focuses on advanced seed genetics and traits through its Seed segment, and offers crop protection products like herbicides and insecticides via its Crop Protection segment, serving farmers worldwide. In its most recent reported quarters, Corteva demonstrated a mixed performance. For Q2 2025, the company reported EPS of $2.20 against an estimate of $1.88, and revenue of $6.46 billion. This followed a Q1 2025 where EPS was $1.13 versus an estimate of $0.88, with revenue at $4.42 billion. Prior to this, Q4 2024 saw actual EPS of $0.32 against an estimate of $0.31, and Q3 2025 reported a narrower loss than anticipated at -$0.23 compared to an estimate of -$0.47. The company has shown a pattern of beating EPS estimates in recent quarters, with Q4 2024, Q1 2025, and Q2 2025 all exceeding analyst expectations, and Q3 2025 showing a less severe loss than projected. Looking at year-over-year growth, the provided data does not offer enough historical context to establish a consistent trajectory. However, the recent trend indicates a positive performance in EPS for the last three reported quarters, with revenue also showing growth in Q1 and Q2 2025 compared to their respective prior year periods (though specific prior year revenue figures are not provided). Recent news highlights analyst sentiment, with UBS raising its price target to $88 and maintaining a Neutral rating, while other firms like Argus and Wells Fargo & Company have also increased targets, reflecting positive analyst views. Corteva has also reached a new 52-week and all-time high, supported by strong analyst sentiment and investor interest, though its Zacks Rank is currently a #3 (Hold). Investors will be watching for continued positive EPS and revenue performance in upcoming quarters, particularly as the company navigates analyst sentiment shifts and its current Zacks Rank. Key will be whether the company can sustain its recent upward momentum and translate positive analyst outlooks into continued financial outperformance.
